explore -WSS

explore

author：fashion 2025-09-30 19:25:12 - browse：9

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Flash flood warnings continue for parts of Missouri, Illinois

focus

entertainment

WSS

Death of patient in Alzheimer’s trial raises question of possible risks

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

#NeedHerScience: shining a light on gender disparities in medicine

#NeedHerScience: shining a light on gender disparities in medicine

WATCH: Why do fingernails fall off when they're damaged?

Sweden knocks USA out of World Cup in penalty kicks

hotspot

explore

focus

How one medical school became remarkably diverse

Death of patient in Alzheimer’s trial raises question of possible risks

Novavax promises a turnaround & Lilly roils the obesity market

Why drug prescriptions should include diagnoses

Drug repurposing or repositioning? The language matters

NFL doctors' conflicts of interest could endanger players, report says

DIEP, the 'gold standard' of breast reconstruction, is under threat

St. Louis police protesters begin picking up checks in $4.9 million settlement

Moonlake's readout produced a cash windfall. Risks remain

It was time to plan for my old age. If only I could stop crying

entertainment

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

The strategy behind pharma's lawsuits over drug pricing reform

How CRISPR works, explained in two minutes

How CRISPR works, explained in two minutes

CDC concerned about possible undetected monkeypox spread in U.K.

Do masks work? RCTs can't tell us

focus

hotspot

entertainment

entertainment